Trials / Recruiting
RecruitingNCT06066346
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Talquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talquetamab | Talquetamab will be administered SC until disease progression |
Timeline
- Start date
- 2023-09-27
- Primary completion
- 2027-10-01
- Completion
- 2027-10-01
- First posted
- 2023-10-04
- Last updated
- 2026-03-04
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06066346. Inclusion in this directory is not an endorsement.